All In Biotech

Drug Trial Radar · NCT00541086

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 3,697 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,697

Actual

Start

Mar 2007

Primary completion

Jul 2020

Study completion Jul 2020

Sponsor

Lead sponsor
Gruppo Italiano Mammella (GIM)Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking use of estrogen by the tumor cells. Anastrozole, letrozole, and exemestane may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether giving tamoxifen followed by anastrozole, letrozole, or exemestane is more effective than giving anastrozole, letrozole, or exemestane alone in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving tamoxifen followed by either anastrozole, letrozole, or exemestane to see how well it works compared to anastrozole, letrozole, or exemestane alone in treating postmenopausal women with hormone-responsive invasive breast cancer that has been completely removed by surgery.

Conditions

  • Breast Cancer

Interventions

  • anastrozoleDrug

    1 mg per day, orally

  • exemestaneDrug

    25 mg per day, orally

  • letrozoleDrug

    2.5 mg per day, orally

  • tamoxifen citrateDrug

    20 mg per day, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survivalTime frame: 5 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Federico II University Medical School

    Naples, Italy

  • Istituto Nazionale per lo Studio e la Cura dei Tumori

    Naples, Italy

  • Seconda Universita di Napoli

    Naples, Italy

  • Arcispedale S. Maria Nuova

    Reggio Emilia, Italy

  • Istituti Fisioterapici Ospitalieri - Roma

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.